HM15275

Phase 2Small molecule

Hanmi Pharmaceutical Company Limited

HM15275 is one of 68 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusRecruiting

Diabetes MellitusActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Recruiting

Diabetes MellitusPhase 2

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

20 2

Insulin 320

Novo Nordisk

Preclinical

43 3

NOVOLIN R

Novo Nordisk

Preclinical

1 4

Adenocard

Astellas

Preclinical

1 5

Dostinex

Golytely

Cipro

Lantus

6 9

HM15275

Hanmi Pharmaceutical Company Limited

Phase 2

1 10

Lixisenatide

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Diabetes Mellitus

NCT07205900

Q4 2027

Phase 2Recruiting

Type 2 Diabetes Mellitus

NCT07527650

Clinical

Trials by Indication[1]

Diabetes Mellitus1 trial

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

Recruiting· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 2·NCT07205900·250 enrolled

Phase 11 trial

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

Completed· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 1·NCT06481098·74 enrolled

Type 2 Diabetes Mellitus1 trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus

Recruiting· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 2·NCT07527650·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HM15275. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HM15275 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HM15275. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hanmi Pharmaceutical Company Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Hanmi Pharmaceutical Company Limited

HM15275

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Diabetes Mellitus1 trial

Phase 11 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News